Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability

Size: px
Start display at page:

Download "Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability"

Transcription

1 Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy Risk Acceptability Versailles, France December 2-4, 2009 Fred A. Mettler Jr. M.,D., M.P.H. New Mexico Federal Regional Medical Center Albuquerque, New Mexico, USA

2 Radiation Protection in Medicine ICRP 105 says.. Justification.. Use of radiation in medicine (level1) of a practice/procedure (level 2) for an individual (level 3) Benefit should exceed risk Optimization of the relationship between tumor control and complications..but there is little guidance on how risk/benefit balance is to be done in medicine or who actually does it

3 Risk Is risk really quantifiable? While many dangers are quantifiable. judgments, values and culture affect acceptability of risk A basic difficulty is that those should or will participate in the risk decision have divergent perspectives Radiation risk and acceptability cannot be dealt with alone. They occur in a world with many other factors

4 Quantitative risk assessment (QRA): Can we do it for cancer therapy? What can go wrong with our system? What is the likelihood of that happening under the current plan? If it does happen what are the consequences? i.e. what is the damage?

5 Can we find an extreme example of radiation and other risks.. to look at how risk acceptability is done?

6

7

8 The radiation protection philosophy and risk acceptability views of an astronaut Ellen Baker, NASA As astronauts our mission risks are high but that does not mean that we should also accept high levels of radiation risk We still do not understand the full range of radiation risks Therefore we rely on you to provide us with the latest information and provide us with the most up-to-date techniques to reduce or minimize radiation risks

9 What is the universe of risk the patient is faced with? A tour of risk through the patients eyes Prostate cancer as an example most common cancer in men

10 Risk acceptance in radiotherapy Who accepts the risk???? The patient.. Isn t that obvious??

11 Can we really expect any normal 70-year old figure out whether to accept the risks and uncertainties that are associated with prostate cancer? Occult tumors Clinical staging PSA screening Cryosurgery Biopsy PSA velocity Impotence Gleason score Watchful waiting Biochemical recurrence IMRT Bone scan/ct/mri Brachytherapy Hormone therapy Radical prostatectomy Survival rate Conformal radiotherapy Robotic surgery

12 The risk/decision pathways for the prostate cancer patient PSA Screen no yes RPP PSA < 4 <4 but rising >4 no Biopsy yes Gleason 6 or less 7 8,9 Staging Clinical no Bone scan/ct/mri yes Robotic External Brachytherapy Both Surgery Radiation? negative equivocal positive no Hormone yes

13 PSA Screen no yes RPP Biopsy yes Gleason 7 8,9 Robotic Risk of anywhere from 15-30% Surgery of being wrong about whether he has cancer at all and it may not make External much difference in outcome Radiation Brachytherapy? Both Percent of patients with PSA < 4 with cancer ~15% Percent of patients with PSA > 4 without cancer ~ 65-75% no PSA screening doubles the 6 incidence or less of diagnosis does not change death rate (NEJM 360: ,2009) negative no Bone scan/ct/mri yes equivocal positive Staging Clinical yes Hormone no

14 Can PSA or Gleason score determine bone metastases or disease extent? PSA < >50 1.7% 5.9% 11.5% 53.3% Gleason score A score of 7 or greater has a 58% accuracy regarding disease confined to the prostate this criteria has a 42% chance of being wrong

15 What are results of bone scans? Staging 9% positive 9% equivocal 82% negative Or ~10% of the time we say we don t know whether you have metastatic disease or which therapy is appropriate Followup - 18% positive - 9% equivocal -73% negative

16 How accurate are the bones scan interpretations?

17 NaF-18 PET/CT bone scan

18 NaF-18 PET/CT bone scan

19 More NaF-18 scans read as equivocal but 8/8 biopsies were negative for malignancy..

20 How accurate is the clinical staging by the physician? Subsequent surgery has shown that about 50% of the time, clinical staging underestimates the spread of disease Or a risk of 50% error if you only rely on your doctors physical examination

21 Which therapy should I have?

22 Risk Perception and communication What you said was not necessarily what you meant and What you said was not necessarily what he heard

23 How the same risk data presented differently affects choice Mortality rate Survival rate Surgery Radiation Surgery Radiation Treatment 10% 0% 90% 100% After 1 yr 32% 23% 68% 77% After 5 yr 66% 78% 34% 22% % choosing RT 44% 18% McNeil NEJM ,1982 assumed lung cancer

24 Where is the data on which therapies work best? I will ask Dr. Google...

25 da Vinci robotic therapy ad

26 Surgery has a better cure rate than brachytherapy

27 Brachytherapy possibly combined with external is almost as good as surgery and with fewer complications

28

29 OK, I ve confused myself enough on all the other issues and I have now decided to do radiation therapy what are my risks from that??

30 Prostate radiotherapy complications External Urinary grade 3 or more 8% GI toxicity grade 3 or more 3-4% Brachytherapy 21% nocturia 12% need β blockers 8-9% erectile dysfunction 6% incontinence 5% rectal injury 3-8% catheter dependent or need surgery

31 What is the radiotherapy accident risk? In the U.S. annually 197,000 patients get external beam radiotherapy for prostate cancer and ~50,000 get brachytherapy

32 92 of 116 cases under-treated

33 What is the second cancer risk from prostate radiotherapy? Depending on what you read Pick a number between 0 and 25%

34 2007 Literature review from mid 1980 to after age adjustment no clear increase was detectable 0% risk

35 2008 The age adjusted rate of SPC for external beam was 2.45/100,000 The hazard ratio for SPC was 1.26 for external beam compared to no radiotherapy (26% increase) No significant differences were seen in the incidence of radiation-induced second primary cancers between the radiation therapy groups

36 2007 approximately one in 70 patients undergoing radiation and surviving more than 10 years will develop secondary cancer.or 1.4% not necessarily due to radiation

37 2009 external Overall incidence of SPC was 8.4% 1747 cases / 100,000 for surgery and radiotherapy 1581 cases/ 100,000 for surgery only..an excess of 374 cases/100,000 was seen in the external radiotherapy group compared to surgery or 0.4% excess risk

38 Even what risk is accepted by the patient does not occur in a void Family Age Quality of life Co-morbidities Financial Availability Trust in physician

39 A large part of risk acceptance is not really done by the patient at all But by Patient Family Physician Institution Manufacturers Regulators Society

40 What I would ask Has the machine been fixed lately? What are the qualifications of the staff? Are there recent changes in staff? What are the data on cure and complication nationally compared to this hospital? During my treatment, how do you check what dose I am getting or have gotten? How long has this particular machine and protocol been used?

41 My conclusions The patient does not really understand all the risks in a complex situation and therefore cannot fully accept the risk The techniques and treatments change rapidly and risk is often not well defined so physicians cannot fully explain the risks Many risks are determined (accepted) by manufacturers, advisory and regulatory bodies who have made decisions

42 My conclusions Radiation risks are not the major issue faced by the patient. There are many other larger risks and unknowns the patient must deal with. Radiation risks are essentially controlled (accepted) by persons other than the patient Risk acceptance largely depends on the trust in the institutions presenting the expert rating and by the previous success and failures of those institutions. (Short 1984)

43 Philosophy of protection (astronaut) patient As (astronauts) patients our (mission) risks are high but that does not mean that we should also accept high levels of radiation risk We still do not understand the full range of radiation risks Therefore we rely on you to provide us with the latest information and provide us with the most up-to-date techniques to reduce or minimize radiation risks

44 Does it work that way all the time??

45

46

47

48

49

50 Thank you

AllinaHealthSystems 1

AllinaHealthSystems 1 2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology

More information

PROSTATE CANCER CONTENT CREATED BY. Learn more at

PROSTATE CANCER CONTENT CREATED BY. Learn more at PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL

More information

Prostate Cancer Incidence

Prostate Cancer Incidence Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases

More information

NICE BULLETIN Diagnosis & treatment of prostate cancer

NICE BULLETIN Diagnosis & treatment of prostate cancer Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

Newer Aspects of Prostate Cancer Underwriting

Newer Aspects of Prostate Cancer Underwriting Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions

More information

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) - Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30

More information

The Prostate Cancer Surgery Tick List. Use these questions as starters for your first meeting with your prostate cancer surgeon.

The Prostate Cancer Surgery Tick List. Use these questions as starters for your first meeting with your prostate cancer surgeon. The Prostate Cancer Surgery Tick List Use these questions as starters for your first meeting with your prostate cancer surgeon. Print these out and had to your doctor at the start of your meeting. Tick

More information

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,

More information

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3

More information

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University

More information

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools

More information

When to worry, when to test?

When to worry, when to test? Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

Treating Prostate Cancer

Treating Prostate Cancer Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and

More information

Outcomes With "Watchful Waiting" in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better

Outcomes With Watchful Waiting in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better 1 sur 5 19/09/2009 07:02 www.medscape.com From Medscape Medical News Outcomes With "Watchful Waiting" in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better Zosia Chustecka September

More information

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk

More information

Helping you make better-informed decisions 1-5

Helping you make better-informed decisions 1-5 Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis

More information

TOOKAD (padeliporfin) Patient Information Guide

TOOKAD (padeliporfin) Patient Information Guide TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Consensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director

Consensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT

More information

Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review

Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Jayatissa R.M.G.C.S.B. (B.Sc.) Department of Radiography/Radiotherapy, Faculty of Allied Health

More information

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last

More information

Prostate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!

Prostate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped! We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is

More information

Chapter 18: Glossary

Chapter 18: Glossary Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is

More information

An educational guide from Genomic Health

An educational guide from Genomic Health Active Surveillance or Immediate Treatment? The Oncotype DX Prostate Cancer Assay helps you and your doctor choose with confidence. For more information, visit OncotypeDX.com. An educational guide from

More information

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of

More information

Area offers new approach to detecting, diagnosing and treating prostate cancer. by ANDREA GABLE

Area offers new approach to detecting, diagnosing and treating prostate cancer. by ANDREA GABLE MAXIMIZING MEN S HEALTH Area offers new approach to detecting, diagnosing and treating prostate cancer by ANDREA GABLE From left, David Lowther, MD; Nayha Dixit; Leigh Collins; Erin Hutchinson; and Robert

More information

General information about prostate cancer

General information about prostate cancer Prostate Cancer General information about prostate cancer Key points Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. Signs of prostate cancer include

More information

3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD

3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive

More information

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.

More information

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES OVERVIEW Diagnosis Laboratory Tests PSA Free and Total PSA PCA-3 4K Score The

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS

More information

The Center for Prostate Care, ProHealth Care Regional Cancer Center, Wisconsin

The Center for Prostate Care, ProHealth Care Regional Cancer Center, Wisconsin The Center for Prostate Care, ProHealth Care Regional Cancer Center, Wisconsin A prostate care coordinator supports, educates, and guides patients through diagnosis, treatment, and follow-up by Don Jewler

More information

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018 Men s Health Topics Jerome Baca, MS, PA-C Albuquerque Urology Associates January 6 th, 2018 1 ns 2 Prostate Cancer (pca) Most common type of cancer in men 45-75yo > 95% is adenocarcinoma: CA arising from

More information

Prostate Cancer Treatment

Prostate Cancer Treatment Scan for mobile link. Prostate Cancer Treatment Prostate cancer overview Prostate cancer is the most common form of cancer in American men, most prevalent in men over age 65 and fairly common in men 50-64

More information

Prostate Cancer Treatment Experts

Prostate Cancer Treatment Experts Prostate Cancer Treatment Experts Category Offering HIFU A Cutting-Edge, Non-Invasive Treatment with Low Risk of Side Effects While prostate cancer is a fairly common disease among men in the US, with

More information

PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO

PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO 1 00:00:00,067 --> 00:00:10,968 2 00:00:10,968 --> 00:00:12,701 So, you were given a decision aid sheet 3 00:00:12,701 --> 00:00:14,567 about prostate

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

Your Guide to Prostate Cancer

Your Guide to Prostate Cancer Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,

More information

MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT

MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:

More information

Active Surveillance for Prostate Cancer

Active Surveillance for Prostate Cancer PATIENT & CAREGIVER EDUCATION Active Surveillance for Prostate Cancer This information explains a treatment for prostate cancer called active surveillance. Not all prostate cancers are the same. Some may

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate

More information

2008_Prostate_Awareness 12/22/08 1:47 PM Page 1

2008_Prostate_Awareness 12/22/08 1:47 PM Page 1 2008_Prostate_Awareness 12/22/08 1:47 PM Page 1 2008_Prostate_Awareness 12/22/08 1:47 PM Page 2 A Message from Dr. Frank Critz Prostate cancer is the most common cancer in men, other than skin cancers.

More information

The Changing Landscape of Prostate Cancer

The Changing Landscape of Prostate Cancer The Changing Landscape of Prostate Cancer helping make the complicated, understandable Marc B. Garnick, MD FACP Clinical Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School

More information

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate

More information

da Vinci Prostatectomy

da Vinci Prostatectomy da Vinci Prostatectomy Justin T. Lee MD Director of Robotic Surgery Urology Associates of North Texas (UANT) USMD Prostate Cancer Center (www.usmdpcc.com) Prostate Cancer Facts Prostate cancer Leading

More information

Taking Control of Your Destiny... Douglas P. Menelly

Taking Control of Your Destiny... Douglas P. Menelly Taking Control of Your Destiny... Douglas P. Menelly Just a regular guy... Agenda Prostate Cancer Statistics PC Treatment Options PC Treatment Side Effects Dad s Story Alternative Treatments PC Mountain

More information

Prostate Cancer in men with germline DNA repair deficiency

Prostate Cancer in men with germline DNA repair deficiency Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,

More information

Prostate cancer: intervention comparisons

Prostate cancer: intervention comparisons National Institute for Health and Care Excellence Guideline version (Draft) Prostate cancer: intervention comparisons [G] Evidence reviews for active surveillance, radical prostatectomy or radical radiotherapy

More information

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason

More information

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...

More information

PET imaging of cancer metabolism is commonly performed with F18

PET imaging of cancer metabolism is commonly performed with F18 PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism

More information

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although

More information

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 1. Medical Student Case-Based Learning Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You

More information

Prostate Cancer. What is prostate cancer?

Prostate Cancer. What is prostate cancer? Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific

More information

Prostatic Cryosurgery and Robotic Prostatectomy

Prostatic Cryosurgery and Robotic Prostatectomy Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/prostatic-cryosurgery-androbotic-prostatectomy/4013/

More information

Prostate Cancer UK s Best Practice Pathway

Prostate Cancer UK s Best Practice Pathway Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason

More information

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?

Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk ADVICE TO

More information

Prostate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC

Prostate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC Prostate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC 1990 Screening The detection of disease in asymptomatic people in order to

More information

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer Jerry Cross 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer From http://prostatesnatchers.blogspot.com/ January 27, 2015 BY MARK SCHOLZ,

More information

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence

More information

Prostate Cancer: from Beginning to End

Prostate Cancer: from Beginning to End Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 146 Effective Health Care Program Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review Executive Summary Background Prostate cancer

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Project Overview Ronald C. Chen, MD MPH Introductions Principal Investigator: Ronald C. Chen, MD MPH ACS Staff: Eileen Tonner,

More information

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical

More information

2011 PROSTATE BRACHYTHERAPY STUDY

2011 PROSTATE BRACHYTHERAPY STUDY 20 PROSTATE BRACHYTHERAPY STUDY CRITERIA Patients receiving prostate brachytherapy at Cox from 2002-200. In this study, we will look at patients with the following prognostic features: PSA

More information

[PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK

[PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK 06 March, 2018 [PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK Document Filetype: PDF 506.4 KB 0 [PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK See information on benefits and safety. We

More information

Prostate Overview Quiz

Prostate Overview Quiz Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the

More information

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.

More information

Economic Model of Multiple Radiation Therapy Treatments for Low-Risk Prostate Cancer: Overview. June 4, Julia Hayes, M.D. Pamela McMahon, Ph.D.

Economic Model of Multiple Radiation Therapy Treatments for Low-Risk Prostate Cancer: Overview. June 4, Julia Hayes, M.D. Pamela McMahon, Ph.D. Economic Model of Multiple Radiation Therapy Treatments for Low-Risk Prostate Cancer: Overview June 4, 2008 Julia Hayes, M.D. Pamela McMahon, Ph.D. ICER Model: Overview Markov cohort model One year cycle

More information

Prostate Cancer Awareness - Prevention, Symptoms and. Treatment

Prostate Cancer Awareness - Prevention, Symptoms and. Treatment Quality Assurance Lunch and Learn Sessions: Prostate Cancer Awareness - Prevention, Symptoms and What s wrong with my prostate? Treatment??? Sponsored by the Chief Engineer s Team and Quality Assurance

More information

Brachytherapy for Prostate Cancer

Brachytherapy for Prostate Cancer Brachytherapy for Prostate Cancer Who should be thinking about this and why... Juanita Crook Professor Radiation Oncology University of Toronto Princess Margaret Hospital Many options watchful waiting?

More information

Deciding on treatment: a step on your journey.

Deciding on treatment: a step on your journey. Deciding on treatment: a step on your journey. One step at a time. After being told that you have prostate cancer, the next step on your journey may be to participate in the decision on which type of treatment

More information

Comparing Radiation Treatments for Prostate Cancer: What Does the Evidence Tell Us?

Comparing Radiation Treatments for Prostate Cancer: What Does the Evidence Tell Us? Comparing Radiation Treatments for Prostate Cancer: What Does the Evidence Tell Us? Dan Ollendorf, MPH 2nd Annual W.B. Ingalls Memorial Prostate Seminar March 7, 2009 Institute for Clinical and Economic

More information

Prostate Cancer Treatment Decision Information Background

Prostate Cancer Treatment Decision Information Background Prostate Cancer Treatment Decision Information Background A group of Radiotherapy Clinics of Georgia (RCOG) prostate cancer (PCa) patients developed this web site, in part, based on a slide presentation

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation

More information

Screening for Disease

Screening for Disease Screening for Disease An Ounce of Prevention is Worth a Pound of Cure. Actually, an ounce of prevention is better than a pound of cure, but if prevention hasn t been effective, perhaps early identification

More information

Radical prostate surgery?

Radical prostate surgery? Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your

More information

OHTAC Recommendation

OHTAC Recommendation OHTAC Recommendation Robotic-Assisted Minimally Invasive Surgery for Gynecologic and Urologic Oncology Presented to the Ontario Health Technology Advisory Committee in August 2010 December 2010 OHTAC Recommendation:

More information

Definition Prostate cancer

Definition Prostate cancer Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation

More information

PROSTATE CANCER: A Primer of Diagnosis and Treatment. Jay C. Lee, MD, FRCSC Clinical Associate Professor University of Calgary

PROSTATE CANCER: A Primer of Diagnosis and Treatment. Jay C. Lee, MD, FRCSC Clinical Associate Professor University of Calgary PROSTATE CANCER: A Primer of Diagnosis and Treatment Jay C. Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document

More information

Prostate Cancer. David Wilkinson MD Gulfshore Urology

Prostate Cancer. David Wilkinson MD Gulfshore Urology Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)

More information

PROSTATE CANCER Amit Gupta MD MPH

PROSTATE CANCER Amit Gupta MD MPH PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment

More information

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services

More information

The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description

The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description In response to an enquiry from the Scottish Radiotherapy Advisory Group Number 37 June 2011 The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology

More information

Cryotherapy for recurrent prostate cancer. Issue date: May 2005

Cryotherapy for recurrent prostate cancer. Issue date: May 2005 Issue date: May 2005 Cryotherapy for recurrent Understanding NICE guidance information for people considering the procedure, and for the public Information about NICE Interventional Procedure Guidance

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

LESSON 5.2 WORKBOOK. What do cancer screens really tell us? Workbook Lesson 5.2

LESSON 5.2 WORKBOOK. What do cancer screens really tell us? Workbook Lesson 5.2 Mortality rate The rate at which people die from a specific cancer. For a complete list of defined terms, see the Glossary. LESSON 5.2 WORKBOOK What do cancer screens really tell us? Treating cancer successfully

More information

c) Do you think radiation treatment for my cancer is better than surgically removing my gland, and if so, why?

c) Do you think radiation treatment for my cancer is better than surgically removing my gland, and if so, why? QUESTIONS TO ASK A RADIATION ONCOLOGIST IF CONSIDERING RADIATION THERAPY FOR DIAGNOSED PROSTATE CANCER For the patient: You should review these questions and determine if the answers would satisfy a better

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

PSA Screening and Prostate Cancer. Rishi Modh, MD

PSA Screening and Prostate Cancer. Rishi Modh, MD PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University

More information

Prostate Cancer Treatments. Hasan Murshed, MD., DABR Radiation Oncology Residency, UAB Fellowship, MDACC Board Certified, ABR

Prostate Cancer Treatments. Hasan Murshed, MD., DABR Radiation Oncology Residency, UAB Fellowship, MDACC Board Certified, ABR Prostate Cancer Treatments Hasan Murshed, MD., DABR Radiation Oncology Residency, UAB Fellowship, MDACC Board Certified, ABR A Brief History of Radiation Wilhelm Roentgen discovered X- rays on November

More information

Localized Prostate Cancer and Its Treatment- A Patient Guide

Localized Prostate Cancer and Its Treatment- A Patient Guide Your Health Matters Localized Prostate Cancer and Its Treatment- A Patient Guide Department of Urology UCSF Helen Diller Family Comprehensive Cancer Center University of California. San Francisco 550 16th

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

f) DATTOLI CANCER CENTER

f) DATTOLI CANCER CENTER f) DATTOLI CANCER CENTER Why Focal Therapies Won't Work Michael Dattoli, MD New prostate cancer treatment theories, therapies and approaches seem to surface every month or so these days. It is a challenge

More information

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The

More information